353 related articles for article (PubMed ID: 23816027)
1. Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading.
Kim IS; Jeong YH; Tantry US; Park Y; Lee DH; Bliden KP; Koh JS; Park JR; Jang JS; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S; Gurbel PA
Am Heart J; 2013 Jul; 166(1):95-103. PubMed ID: 23816027
[TBL] [Abstract][Full Text] [Related]
2. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
[TBL] [Abstract][Full Text] [Related]
4. Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry.
Danese E; Fava C; Beltrame F; Tavella D; Calabria S; Benati M; Gelati M; Gottardo R; Tagliaro F; Guidi GC; Cattaneo M; Minuz P
J Thromb Haemost; 2016 Feb; 14(2):282-93. PubMed ID: 26576037
[TBL] [Abstract][Full Text] [Related]
5. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
Stellbaum C; Ayral Y; Morguet A; Schultheiss HP; Rauch U
Cardiovasc Revasc Med; 2012; 13(3):159-66. PubMed ID: 22503564
[TBL] [Abstract][Full Text] [Related]
6. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495
[TBL] [Abstract][Full Text] [Related]
7. Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study.
Park Y; Jeong YH; Tantry US; Ahn JH; Kim KH; Koh JS; Park JR; Hwang SJ; Kwak CH; Hwang JY; Gurbel PA
Thromb Haemost; 2014 Dec; 112(6):1198-208. PubMed ID: 25182660
[TBL] [Abstract][Full Text] [Related]
8. Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity.
Aradi D; Rideg O; Vorobcsuk A; Magyarlaki T; Magyari B; Kónyi A; Pintér T; Horváth IG; Komócsi A
Eur J Clin Invest; 2012 Apr; 42(4):384-92. PubMed ID: 21902692
[TBL] [Abstract][Full Text] [Related]
9. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
[TBL] [Abstract][Full Text] [Related]
10. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
Freynhofer MK; Brozovic I; Bruno V; Farhan S; Vogel B; Jakl G; Willheim M; Hübl W; Wojta J; Huber K
Thromb Haemost; 2011 Aug; 106(2):230-9. PubMed ID: 21614416
[TBL] [Abstract][Full Text] [Related]
11. Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay.
Abtan J; Silvain J; Kerneis M; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Collet JP; Montalescot G
Thromb Haemost; 2013 Nov; 110(5):1055-64. PubMed ID: 23925438
[TBL] [Abstract][Full Text] [Related]
12. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
Aleil B; Jacquemin L; De Poli F; Zaehringer M; Collet JP; Montalescot G; Cazenave JP; Dickele MC; Monassier JP; Gachet C
JACC Cardiovasc Interv; 2008 Dec; 1(6):631-8. PubMed ID: 19463377
[TBL] [Abstract][Full Text] [Related]
13. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
[TBL] [Abstract][Full Text] [Related]
14. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.
El Ghannudi S; Ohlmann P; Meyer N; Wiesel ML; Radulescu B; Chauvin M; Bareiss P; Gachet C; Morel O
JACC Cardiovasc Interv; 2010 Jun; 3(6):648-56. PubMed ID: 20630458
[TBL] [Abstract][Full Text] [Related]
15. Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials.
Lemesle G; Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM
Platelets; 2014; 25(7):499-505. PubMed ID: 24176022
[TBL] [Abstract][Full Text] [Related]
16. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
[TBL] [Abstract][Full Text] [Related]
17. The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.
Jakubowski JA; Angiolillo DJ; Zhou C; Small DS; Moser BA; Ten Berg JM; Brown PB; James S; Winters KJ; Erlinge D
Thromb Res; 2014 Sep; 134(3):552-7. PubMed ID: 25022828
[TBL] [Abstract][Full Text] [Related]
18. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.
Bouman HJ; Parlak E; van Werkum JW; Breet NJ; ten Cate H; Hackeng CM; ten Berg JM; Taubert D
J Thromb Haemost; 2010 Mar; 8(3):482-8. PubMed ID: 20040042
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
Cuisset T; Grosdidier C; Loundou AD; Quilici J; Loosveld M; Camoin L; Pankert M; Beguin S; Lambert M; Morange PE; Bonnet JL; Alessi MC
JACC Cardiovasc Interv; 2013 Aug; 6(8):854-63. PubMed ID: 23968703
[TBL] [Abstract][Full Text] [Related]
20. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]